source
- Former Galapagos CEO Paul Stoffels aims to revive cell therapy projects at new biotech Armed CellPaul Stoffels, who recently stepped down as chief executive of Belgian drug developer Galapagos, is turning his attention to cell‑based therapies. After leaving Galapagos last year, Stoffels has j…
- Osivax shifts to combination strategy after Phase 2b flu vaccine setbackOsivax, a French biotech, reported that its lead influenza vaccine candidate did not meet primary endpoints in a Phase 2b study. The trial, which evaluated the vaccine as a standalone product, sho…